COVID‐19 as a trigger of Guillain‐Barré syndrome: A review of the molecular mechanism
Open Access
- 16 May 2023
- journal article
- review article
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 11 (5), e875
- https://doi.org/10.1002/iid3.875
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a pandemic with serious complications. After coronavirus disease 2019 (COVID-19), several post-acute COVID-19 syndromes (PACSs) and long-COVID sequels were reported. PACSs involve many organs, including the nervous, gustatory, and immune systems. One of the PACSs after SARS-CoV-2 infection and vaccination is Guillain-Barre syndrome (GBS). The incidence rate of GBS after SARS-CoV-2 infection or vaccination is low. However, the high prevalence of COVID-19 and severe complications of GBS, for example, autonomic dysfunction and respiratory failure, highlight the importance of post-COVID-19 GBS. It is while patients with simultaneous COVID-19 and GBS seem to have higher admission rates to the intensive care unit, and demyelination is more aggressive in post-COVID-19 GBS patients. SARS-CoV-2 can trigger GBS via several pathways like direct neurotropism and neurovirulence, microvascular dysfunction and oxidative stress, immune system disruption, molecular mimicry, and autoantibody production. Although there are few molecular studies on the molecular and cellular mechanisms of GBS occurrence after SARS-CoV-2 infection and vaccination, we aimed to discuss the possible pathomechanism of post-COVID-19 GBS by gathering the most recent molecular evidence.Keywords
This publication has 177 references indexed in Scilit:
- 3-Nitrotyrosine: A biomarker of nitrogen free radical species modified proteins in systemic autoimmunogenic conditionsHuman Immunology, 2013
- The role of gut microbiota in immune homeostasis and autoimmunityGut Microbes, 2012
- Population Incidence of Guillain-Barré Syndrome: A Systematic Review and Meta-AnalysisNeuroepidemiology, 2011
- Serum and Cerebrospinal Fluid Antioxidant Activity and Lipid Peroxidation in Guillain–Barre Syndrome and Multiple Sclerosis PatientsInternational Journal of Neuroscience, 2010
- A Case of Diabetic Neuropathy Combined with Guillain-Barre SyndromeThe Korean Journal of Internal Medicine, 2010
- Pathophysiological actions of neuropathy‐related anti‐ganglioside antibodies at the neuromuscular junctionJournal Of Physiology-London, 2009
- Vaccines and Guillain-Barré SyndromeDrug Safety, 2009
- The Epidemiology of Guillain-Barré Syndrome WorldwideNeuroepidemiology, 2008
- Deterioration after Guillain-Barre syndrome: recurrence, treatment-related fluctuation or CIDP?Journal of Neurology, Neurosurgery & Psychiatry, 2008
- Guillain–Barré syndrome associated with cytomegalovirus infection after allogeneic hematopoietic stem cell transplantationTransplant Infectious Disease, 2005